M&A Deal Summary |
|
|---|---|
| Date | 2020-11-30 |
| Target | Sunesis |
| Sector | Life Science |
| Buyer(s) | Viracta Therapeutics |
| Sellers(s) |
Alta Partners
Nexus Life Science Partners Bay City Capital |
| Deal Type | Merger |
| Advisor(s) | MTS Health Partners (Financial) Cooley (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 2007 |
| Sector | Life Science |
| Employees | 40 |
| Revenue | 51M USD (2023) |
Viracta Therapeutics is a precision oncology company targeting virus-associated malignancies. Viracta’s proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in Phase 2 clinical trial for EBV-positive lymphomas. Viracta Therapeutics was founded in 2007 and is headquartered in Cardiff, California.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector (Life Science) | 1 of 1 |
| Type (Merger) | 1 of 1 |
| State (California) | 1 of 1 |
| Country (United States) | 1 of 1 |
| Year (2020) | 1 of 1 |
| Category | Venture Capital Firm |
|---|---|
| Founded | 1996 |
| PE ASSETS | 2.6B USD |
| Size | Large |
| Type | Sector Focused |
Alta Partners is a venture capital firm that targets investments in early and later stage life science companies, including biopharmaceuticals, medical technology, and information technology businesses. Alta was formed as an early stage investor but has since expanded its investment range to provide later stage growth capital to private and young public companies. Alta was established in 1996 and is headquartered in San Francisco, California.
| DEAL STATS | # |
|---|---|
| Overall | 84 of 85 |
| Sector (Life Science) | 65 of 65 |
| Type (Merger) | 2 of 2 |
| State (California) | 41 of 41 |
| Country (United States) | 74 of 75 |
| Year (2020) | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-11-01 |
Intarcia Therapeutics
Boston, Massachusetts, United States Intarcia Therapeutics is a biopharmaceutical company applying a targeted approach to the acquisition, development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. Intarcia Therapeutics is based in Boston, Massachusetts. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-02-04 |
Bioventus
Durham, North Carolina, United States Bioventus provides clinical and cost-effective therapies and diagnostics to help patients regain active lifestyles. The company's innovative products include bone stimulation devices and osteoarthritis joint fluid therapies. Bioventus was incorporated in 2011 and is based in Durham, North Carolina. |
Sell | - |
| Category | Growth Capital Firm |
|---|---|
| Founded | 2001 |
| Size | Small |
| Type | Sector Focused |
Nexus Life Science Partners is a private equity firm that targets private and public healthcare companies located within the United States and around the world. The Firm's focus is on the growth segments of the healthcare industry. In particular, Nexus looks for product-driven life sciences companies developing breakthrough therapeutics for clinical needs, positively altering disease course and associated costs. The firm seeks for each private investment a potential for liquidity within 24 months after initial investment, as well as a 2-3 times return on invested capital. Nexus Life Science Partners was formed in 2001, and is based in New York, New York.
| DEAL STATS | # |
|---|---|
| Overall | 22 of 22 |
| Sector (Life Science) | 18 of 18 |
| Type (Merger) | 1 of 1 |
| State (California) | 6 of 6 |
| Country (United States) | 19 of 19 |
| Year (2020) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-12-20 |
Gentium
Villa Guardia, Italy Gentium S.p.A. (GENT) specializes in potential therapeutic agents, the active ingredients of which are derived from natural sources. They are developing Defibrotide for severe Hepatic Veno-Occlusive Disease (VOD), a potential complication of stem cell transplantation. Their other products include heparin calcium and urokinase. |
Sell | $1.0B |
| Category | Venture Capital Firm |
|---|---|
| Founded | 1997 |
| PE ASSETS | 1.3B USD |
| Size | Large |
| Type | Sector Focused |
Bay City Capital LLC was established in 1997 as an equal partnership between The Craves Group and certain Pritzker family business interests for the purpose of managing investment funds in the life sciences industry. Bay City looks for opportunities at all stages of development in biopharmaceuticals, drug discovery, medical devices and diagnostics. Bay City Capital is based in San Francisco, California.
| DEAL STATS | # |
|---|---|
| Overall | 62 of 63 |
| Sector (Life Science) | 45 of 46 |
| Type (Merger) | 4 of 4 |
| State (California) | 33 of 33 |
| Country (United States) | 59 of 60 |
| Year (2020) | 4 of 4 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-11-01 |
Intarcia Therapeutics
Boston, Massachusetts, United States Intarcia Therapeutics is a biopharmaceutical company applying a targeted approach to the acquisition, development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. Intarcia Therapeutics is based in Boston, Massachusetts. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-06-27 |
Epizyme
Cambridge, Massachusetts, United States Epizyme is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme was founded in 2007 and is based in Cambridge, Massachusetts. |
Sell | $247M |
